Buy ACRV by Dec 29, 2026.

Two studies published this week add support for $ACRV’s drug ACR-368(prexasertib) Study 1: CAF-1 / chromatin assembly + prexasertib study: https://www.biorxiv.org/content/10.64898/2026.09.27.754407v1 Study looked into CHK1 inhibition in cancer cells with defective chromatin assembly. Study shows that treatment with prexasertib let to significantly greater DNA damage, premature mitosis, and loss of viability. Study 2: DS5 / patient-derived tumor drug-screening study: https://www.biorxiv.org/content/10.64898/2026.09.22.753533v1 Shows prexasertib as one of the top most sensitive drugs in two separate testing models for pediatric brain cancer models. …